Canada Launches New Advisory Committee on Preventative Cancer Screening
The Canadian federal government has established a new 14-member advisory committee to provide guidelines on preventative cancer screenings, led by Dr. David Keegan. The committee replaces a suspended task force that faced controversy in March 2025 over its decision not to recommend breast cancer screening for women under 50. The move addresses calls from medical experts and advocacy groups to update screening recommendations, particularly regarding mammogram age eligibility.
Canada's federal government has launched a new advisory committee on preventive health care to develop screening guidelines for cancers including cervical and breast cancer. The 14-member panel, chaired by Dr. David Keegan, a family doctor and medical professor at the University of Calgary, replaces a task force that was suspended in March 2025 after recommending against routine breast cancer screening for women under 50. That decision had drawn criticism from medical experts, including the Canadian Cancer Society, which recommended lowering the mammogram screening age to 40. Advocacy groups such as Dense Breasts Canada have welcomed the new committee's formation and are urging it to act quickly to update the guidelines. The federal government states that the committee includes members with diverse expertise and backgrounds.
What different sources said
- Global News CanadaCenter
Canada is launching a new panel on preventative cancer screenings
Related
Sydney Psychiatrist Retains Medical License After Sexual Assault Conviction
Gopi Ilawala, a Sydney psychiatrist convicted of sexually assaulting an intoxicated colleague in 2022, has been allowed to continue practicing medicine despite the state health regulator seeking to have his registration cancelled. The New South Wales Civil and Administrative Tribunal reprimanded him and imposed conditions rather than striking him off, citing his remorse, lack of prior convictions, and support from two senior psychiatrists. The decision raises questions about professional accountability and public protection in medical regulation.
Australia's TGA to crack down on illegal peptides; government allocates $100m for arthritis research
Australia's Therapeutic Goods Administration has announced a crackdown on illegal peptides due to a surge in imports and online advertising, designating them a priority focus area. The federal government has simultaneously committed $100 million to medical research into arthritis prevention, diagnosis, and treatment. These developments reflect growing regulatory concerns about unregulated drugs and increased investment in chronic disease research.
GLP-1 Drugs Like Ozempic May Help ADHD Symptoms, According to Patient Reports and Clinical Observations
Social media users and some patients are reporting that GLP-1 receptor agonist drugs like Ozempic appear to improve ADHD symptoms, including increased focus, reduced procrastination, and better impulse control. GLP-1s were originally developed to treat Type 2 diabetes but are being studied for various other conditions. While anecdotal reports are growing, no formal clinical trials are currently testing these drugs specifically for ADHD, and the mechanism behind any potential benefit remains unclear.